The Forgotten Epidemic: São Paulo's 1974 Meningitis Crisis, Military Censorship, and the Warning Serogroup B Carries Today

In the winter of 1974, São Paulo was in the grip of one of the worst meningococcal meningitis epidemics in modern urban history. Hospitals were overwhelmed. Families lost children overnight. And for months, the military government tried to hide it. This article is the full story — and an argument that it is not only history.

How It Started — And Why It Spread So Fast

Before 1970, meningococcal disease was relatively uncommon in Brazil. The first cases of what would become the largest urban meningococcal epidemic in the country's history appeared in mid-1971, primarily in the southern periphery of São Paulo — neighborhoods like Santo Amaro, characterized by rapid population growth, precarious housing, poor ventilation, and limited healthcare access.

The causative agent was Neisseria meningitidis serogroup C. The bacterium spreads through respiratory droplets — in exactly the conditions that the periphery of a rapidly industrializing city in the early 1970s provided: overcrowded dwellings, shared sleeping spaces, long daily commutes on packed public transport, and limited access to primary care that might have detected and isolated early cases.

The incidence figures tell the story of the epidemic's acceleration with brutal clarity. From 2.16 cases per 100,000 inhabitants in 1970, the city moved to nearly 30 per 100,000 by 1973. And then 1974 arrived — with a second wave of serogroup A overlapping with the ongoing serogroup C outbreak. The incidence that year reached 179 cases per 100,000 in the city of São Paulo — one of the highest urban rates of meningococcal disease ever recorded anywhere in the world.

What Meningococcal Disease Does — The Clinical Reality

Meningococcal disease presents in two primary forms that can occur separately or simultaneously. Meningococcal meningitis involves bacterial infection of the meninges — the membranes surrounding the brain and spinal cord — producing the classic triad of fever, severe headache, and neck stiffness. Meningococcemia — also called meningococcal septicemia — involves bacterial invasion of the bloodstream, characterized by the appearance of a purpuric rash: purple-red, non-blanching spots on the skin that indicate blood leaking into tissue from damaged small vessels.

The speed of progression is what distinguishes meningococcal disease from most other serious infections. A patient can be well in the morning and dead by nightfall. The purpuric rash — when it appears — is a late sign; waiting for it before acting is already waiting too long. In the 1974 São Paulo epidemic, many families brought children to hospital already in advanced disease. Case fatality rates, while improving as clinical experience developed, ranged from 15 percent early in the epidemic to approximately 8 percent at peak — which, applied to tens of thousands of cases, represents thousands of deaths.

The Censorship — A Dictatorship's Most Dangerous Decision

Brazil in the early 1970s was governed by the military dictatorship of Emílio Garrastazu Médici — the most repressive phase of the military regime that had controlled the country since 1964. The Médici government was characterized by systematic censorship of the press, brutal suppression of political dissent, and the projection of a carefully curated national image centered on the "economic miracle" — the period of rapid GDP growth that the regime used as its primary justification for authoritarian rule.

An epidemic of this scale was incompatible with that image. The government's initial response was to downplay the outbreak — to minimize reporting, delay official acknowledgment, and limit the public health response in ways that prioritized political optics over lives. Information that could have warned communities, prompted earlier medical consultation, and accelerated the response was suppressed for months.

The epidemic had begun, as epidemics often do, in the communities with least political voice — the working-class periphery of São Paulo. For as long as it could be contained there, it remained manageable as a political problem. When it reached the wealthier center of the city — when the middle class began losing children — the political calculus changed. The government finally acknowledged the scale of the crisis in 1974, by which point the epidemic had been running for three years and the mortality count was already catastrophic.

The 1975 Vaccination Campaign — And What It Built

When the government finally acted, it acted at a scale Brazil had never previously attempted. In 1975, a mass vaccination campaign was launched using a bivalent meningococcal vaccine covering serogroups A and C. The images from that campaign are some of the most remarkable in the history of Brazilian public health: kilometer-long queues at Viaduto do Chá, in the Vale do Anhangabaú, at vaccination posts across the city and country. Millions of people — children and adults, from every social class — waiting for hours to receive a dose.

The logistical scale required emergency importation of millions of doses, and the government — understanding that dependence on foreign vaccine supply had been exposed as a critical vulnerability — negotiated a technology transfer agreement with the Pasteur Institute in France. That agreement had consequences that extended far beyond the epidemic: in 1976, Bio-Manguinhos — the Fiocruz biomedical production unit — was significantly strengthened specifically because of this crisis. By 1977, Brazil was producing meningococcal vaccines domestically at scale.

Cases dropped dramatically through 1976 and normalized by 1977. The epidemic was broken — by the combination of mass vaccination, the development of natural immunity in the surviving population, and improved clinical management. The 1975 campaign remains one of the most significant achievements in the history of Brazilian public health, and one of the most direct examples of how a public health crisis, responded to at sufficient scale, can be brought under control.

Serogroup B Today — The Gap That Remains

The 1974 epidemic was caused by serogroups C and A. Today, the national SUS vaccination program provides protection against serogroups C (since the 1990s) and ACWY (since July 2025, as a booster at 12 months). This coverage is real and meaningful — it addresses the strains that drove the worst epidemic in Brazilian history.

But the epidemiological landscape has shifted. Serogroup B now accounts for approximately 50 to 60 percent of invasive meningococcal disease cases in Brazil — particularly in children under five, the age group most vulnerable to severe outcomes. And the MenB vaccine — a recombinant protein vaccine (Bexsero) proven effective against serogroup B — is not part of the national SUS calendar. It is available only in the private healthcare network, at a cost that places it out of reach for the majority of Brazilian families.

In April 2026, the Conitec — Brazil's national health technology assessment commission — declined to incorporate the MenB vaccine into the SUS calendar, citing cost-benefit analysis, estimated expenditure of over R$ 5.5 billion over five years, and limited supply capacity. The decision was defensible on health economics grounds given the current endemic (rather than epidemic) nature of serogroup B disease. It does not eliminate the underlying epidemiological vulnerability.

Five Conditions That Could Change the Picture

Research published in JAMA and detailed analyses of historical and contemporary meningococcal outbreaks consistently identify a set of risk factors that, when present simultaneously, create conditions favorable for a major outbreak. None of these factors alone is sufficient. Their convergence is what epidemiologists watch for.

The Lesson That Connects 1974 to 2026

In May and June 2026, the Instituto de Infectologia Emílio Ribas in São Paulo made international news — first because of a man initially investigated as a possible Ebola case who was ultimately diagnosed with meningococcal meningitis, and subsequently because of the public discussion that diagnosis reopened about meningococcal disease in Brazil. The same hospital. A different century. The same disease family.

The 1974 epidemic is not ancient history. It is within the living memory of Brazilian physicians, policymakers, and families who lived through it. The institutions it built — Fiocruz's production capacity, the national immunization program, the surveillance infrastructure — were built on that experience. The lesson it carries is precise: meningococcal disease, when it finds a large susceptible population under the right conditions, moves faster than any response system can comfortably absorb. The time to act is before the outbreak begins.